Drug Pipeline
New drugs likely to offer patients more options. Key consideration for payors will be effectively balancing high — and rising — price tags with appropriate access. More
Feature
“Specialty Drugs”
39 result(s)
Drug Pipeline
CVS Health provides an early look at some key Breakthrough Therapies expected to be reviewed by the FDA in 2020 as well as the associated cost implications and expected approval... More
Feature
Drug Pipeline
New drugs to treat migraine are approaching approval and could bring relief for many patients, but they portend higher costs. Ongoing monitoring and appropriate utilization... More
Feature
Specialty
CVS Health is helping ensure a better member experience by simplifying the onboarding process and getting appropriate specialty therapies to members faster. More
Briefing
Care Management
Payors can better manage oncology costs by optimizing therapy regimen selection using evidence-based guidelines directly integrated into our proprietary Novologix platform. More
Video
Specialty
CVS Health uses its integrated model to manage specialty spend across benefits and help positively impact clinical and financial outcomes. More
Briefing
Drug Pipeline
Biosimilars are a critical tool PBMs can use to help increase market competition and lower costs – we made changes to our template formularies for categories that now have... More
Feature
Specialty
Specialty spend continues to grow rapidly; CVS Health continues to innovate with strategies that reduced the trend impact of inflation significantly, to 1.7 percent. More
Video
Specialty
Research published by Coram shows that helping patients transition to at-home or ambulatory center infusion treatments can be beneficial to both patients and payors. More
Briefing
Specialty
Key drugs to watch for in the specialty pharmacy pipeline Q4 2018–Q1 2019 More
Specialty Report